GLP-1 is a gut hormone. So why are we only talking about the drug - and not the gut that makes it?
Something seismic is happening in medicine. In five years, GLP-1 receptor agonists - Ozempic, Wegovy, Mounjaro - have gone from diabetes drugs to a global cultural phenomenon. Prescriptions for obesity alone are up 587% since 2019. One in eight American adults has now taken one. Among women aged 50 to 64, the figure is one in five.
What almost no one is talking about is where GLP-1 comes from. Not a laboratory. Not a syringe. GLP-1 - glucagon-like peptide 1 - is produced naturally in the gut, by specialised L cells lining the intestinal wall. The microbiome feeds those cells. Gut bacteria produce the short-chain fatty acids and bile acid signals that trigger GLP-1 secretion. A disrupted gut microbiome means a disrupted signal. And a disrupted signal means a body that has lost its natural metabolic governor - the one the injectable drugs are trying to replace.
The Epidemic in Numbers
|
587% Rise in GLP-1 prescriptions for obesity, 2019–2024 FAIR Health, 2025 |
1,961% Jump in GLP-1 use among people without diabetes FAIR Health, 2025 |
1 in 5 Women aged 50–64 who have used a GLP-1 drug RAND American Life Panel, 2025 |
74–84% Semaglutide users who experience GI adverse events in trials Frontiers in Endocrinology, 2025 |
|
>50% Semaglutide users who discontinue within 12 months BMJ, 2024 |
1bn+ People with obesity globally WHO, 2025 |
<10% Of those who need GLP-1 drugs projected to access them by 2030 WHO, 2025 |
19.1M US patients currently tracked on GLP-1 prescriptions Pharmacy records, 2025 |
The Conversation No One Is Having
GLP-1 is not an artificial construct. It is a hormone your gut has always made - a finely calibrated signal that regulates appetite, blood sugar, gastric emptying, inflammation, and metabolic health. The injectable drugs work because they mimic it. But the reason so many people need those drugs is precisely because their gut has stopped producing enough of its own.
Decades of ultra-processed food, antibiotic overuse, chronic stress, and sedentary living have systematically dismantled the microbial infrastructure that produces GLP-1 naturally. The result is a global population with compromised gut diversity, impaired metabolic signalling, and rising rates of obesity, diabetes, and inflammatory disease. The drugs arrived to treat the symptoms of a gut crisis. But the gut crisis itself remains entirely unaddressed.
The Drug's Own Problem
Microbiome starvation
GLP-1 drugs suppress appetite so profoundly that nutrient intake drops below what the microbiome needs to sustain diversity. Research confirms that the resulting dietary restriction reduces beneficial bacterial populations - the very populations that produce GLP-1 naturally. The drug erodes the system it is mimicking.
Gut barrier compromise
The same GI side effects experienced by 74–84% of semaglutide users - nausea, vomiting, diarrhoea, constipation - are not incidental discomforts. They are signals of gut barrier disruption. Compromised intestinal integrity drives systemic inflammation that persists long after acute symptoms resolve.
The discontinuation crisis
Over 50% of users stop within one year, most citing intolerable side effects. For many, the gut effects are the primary reason. Weight regain follows rapidly. Without addressing the underlying gut health environment, neither the drug nor the outcome can be sustained.
In His Own Words
“The GLP-1 drugs are extraordinary in what they achieve pharmacologically. But they are treating the output of a broken system, not the system itself. GLP-1 is a gut hormone. It is made by gut bacteria. The epidemic of metabolic dysfunction we are living through is fundamentally an epidemic of gut dysfunction. ID² was designed to restore the microbial architecture that produces GLP-1 naturally - to rebuild the terrain that makes the drug unnecessary for some, and tolerable and sustainable for those who need it. You cannot medicate your way out of a broken gut. You have to fix the gut.”
- Professor Paul Clayton, Chief Scientific Advisor, LYMA
Why ID² Changes the Equation
1 - Restore natural GLP-1 production
The microbiome produces short-chain fatty acids - butyrate, propionate, acetate - that directly stimulate intestinal L cells to secrete GLP-1. ID² is formulated to feed and rebuild the specific bacterial populations responsible for this production. For those who do not want pharmaceutical intervention, ID² supports the body’s own metabolic signalling pathway. For those who do, it creates the gut microbiome conditions in which that signal was always meant to operate.
ID² supports natural GLP-1 production by rebuilding the microbial populations your gut relies on.
2 - Protect the microbiome of GLP-1 drug users
For the millions already on Ozempic, Wegovy, or Mounjaro, appetite suppression is also microbiome suppression. Nutrient restriction starves beneficial bacteria. ID² provides the prebiotic and probiotic substrate the gut microbiome needs to maintain diversity under reduced caloric load - protecting the gut environment that the drug itself is threatening.
3 - Resolve the GI side effect crisis
The 74–84% of users experiencing GI distress are experiencing gut barrier disruption. ID² works directly to restore intestinal integrity - reducing permeability, calming the inflammatory response, and rebuilding the mucosal lining that GLP-1 therapy compromises. Less discomfort means better adherence. Better adherence means better outcomes.
4 - Address the root cause, not just the signal
The drugs mimic a hormone. ID² rebuilds the system that makes it. For those who cannot access or afford GLP-1 medication - and by 2030 that will be more than 90% of those who need it - restoring gut health is the only viable path. For everyone else, it is the foundation on which pharmacological intervention should sit.
The GLP-1 revolution has put a spotlight on metabolic health unlike anything before it. But the spotlight has been aimed at the drug, not the organ that makes the hormone. The gut is where this story begins and ends. Fix the gut, and you restore the signal. Restore the signal, and the body remembers how to regulate itself. That is what ID² is built to do.
LYMA ID² · The Gut Behind the Hormone.
Sources
BMJ (2024) - GLP-1 discontinuation rates: https://www.bmj.com
FAIR Health (2025) - Prescription surge data & non-diabetic use: https://www.fairhealth.org
RAND American Life Panel (2025) - Demographics of GLP-1 use: https://www.rand.org/research/american-life-panel.html
Frontiers in Endocrinology (2025) - GI adverse events in semaglutide trials: https://www.frontiersin.org/journals/endocrinology
ICER (2025) - Cost-effectiveness and access projections: https://icer.org
WHO (2025) - Global obesity figures, 3.7M deaths, projected access <10% by 2030: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
